KR20060034650A - 룩-스루 돌연변이 - Google Patents

룩-스루 돌연변이 Download PDF

Info

Publication number
KR20060034650A
KR20060034650A KR1020057025136A KR20057025136A KR20060034650A KR 20060034650 A KR20060034650 A KR 20060034650A KR 1020057025136 A KR1020057025136 A KR 1020057025136A KR 20057025136 A KR20057025136 A KR 20057025136A KR 20060034650 A KR20060034650 A KR 20060034650A
Authority
KR
South Korea
Prior art keywords
polypeptide
amino acid
polynucleotides
ser
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057025136A
Other languages
English (en)
Korean (ko)
Inventor
로베르토 크레아
Original Assignee
바이오렌 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오렌 인코포레이티드 filed Critical 바이오렌 인코포레이티드
Publication of KR20060034650A publication Critical patent/KR20060034650A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020057025136A 2003-06-27 2004-06-25 룩-스루 돌연변이 Withdrawn KR20060034650A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48328203P 2003-06-27 2003-06-27
US60/483,282 2003-06-27

Publications (1)

Publication Number Publication Date
KR20060034650A true KR20060034650A (ko) 2006-04-24

Family

ID=33563915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057025136A Withdrawn KR20060034650A (ko) 2003-06-27 2004-06-25 룩-스루 돌연변이

Country Status (14)

Country Link
US (1) US20050136428A1 (https=)
EP (1) EP1660655B1 (https=)
JP (2) JP4791960B2 (https=)
KR (1) KR20060034650A (https=)
CN (1) CN1836041A (https=)
AU (1) AU2004254352A1 (https=)
BR (1) BRPI0412007A (https=)
CA (1) CA2542192C (https=)
ES (1) ES2609102T3 (https=)
IL (1) IL172736A0 (https=)
NO (1) NO20060108L (https=)
RU (1) RU2005140664A (https=)
WO (1) WO2005003345A2 (https=)
ZA (1) ZA200510460B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092458A1 (ko) * 2012-12-11 2014-06-19 연세대학교 산학협력단 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329725B1 (en) * 2003-10-29 2008-02-12 Nastech Pharmaceutical Company Inc. Phage displayed Trp cage ligands
CA2572961C (en) 2004-07-06 2016-08-16 Bioren, Inc. Universal antibody libraries
CA2573259A1 (en) * 2004-07-06 2006-02-09 Bioren Inc. High affinity anti-tnf-alpha antibodies and method
JP4939410B2 (ja) 2004-07-06 2012-05-23 バイオレン，インク． 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
WO2006094234A1 (en) * 2005-03-03 2006-09-08 Xencor, Inc. Methods for the design of libraries of protein variants
US20080207467A1 (en) * 2005-03-03 2008-08-28 Xencor, Inc. Methods for the design of libraries of protein variants
CA2605697A1 (en) * 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
JP2009515516A (ja) * 2005-11-14 2009-04-16 バイオレン・インク 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
WO2007086994A1 (en) * 2005-11-15 2007-08-02 Balyasnikova Irina V Single chain fragment of monoclonal antibody 9b9 and uses thereof
CA2634080A1 (en) 2005-12-20 2007-06-28 Arana Therapeutics Limited Anti-inflammatory dab
CN101400703B (zh) 2006-02-01 2013-05-08 赛法隆澳大利亚控股有限公司 结构域抗体构建体
US7704953B2 (en) * 2006-02-17 2010-04-27 Mdrna, Inc. Phage displayed cell binding peptides
WO2007112054A2 (en) * 2006-03-23 2007-10-04 Sea Lane Biotechnologies, Llc Facilitation of translocation of molecules through the gastrointestinal tract
EP2024393A2 (en) 2006-05-15 2009-02-18 Sea Lane Biotechnologies,llc. Neutralizing antibodies to influenza viruses
WO2007136840A2 (en) * 2006-05-20 2007-11-29 Codon Devices, Inc. Nucleic acid library design and assembly
EP2057191A1 (en) 2006-08-18 2009-05-13 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
EP2069558B1 (en) * 2006-10-02 2013-05-01 Sea Lane Biotechnologies,llc. Design and construction of diverse synthetic peptide and polypeptide libraries
US20080287320A1 (en) * 2006-10-04 2008-11-20 Codon Devices Libraries and their design and assembly
KR20100028031A (ko) * 2007-06-06 2010-03-11 다니스코 유에스 인크. 단백질 특성의 개선 방법
WO2009009045A2 (en) * 2007-07-10 2009-01-15 The Scripps Research Institute Escape libraries of target polypeptides
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
EP2220120A2 (en) 2007-11-27 2010-08-25 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
EP2131245A3 (en) * 2008-06-02 2012-08-01 ASML Netherlands BV Lithographic apparatus and its focus determination method
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
ES2643034T3 (es) 2009-06-05 2017-11-21 Ablynx N.V. Construcciones de Nanobody contra el virus respiratorio sincicial humano (VRSH) trivalentes para la prevención y/o el tratamiento de infecciones de las vías respiratorias
ES2652340T3 (es) * 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2494046B1 (en) 2009-10-30 2018-09-12 Novartis AG Universal fibronectin type iii bottom-side binding domain libraries
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
CN107903321A (zh) 2010-07-30 2018-04-13 诺华有限公司 纤连蛋白摇篮分子和其库
EP2647704B1 (en) 2010-12-01 2017-11-01 Mitsubishi Tanabe Pharma Corporation Polynucleotide construct capable of presenting fab in acellular translation system, and method for manufacturing and screening fab using same
US10138302B2 (en) 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
SG11201404532XA (en) 2012-03-02 2014-08-28 Ablynx Nv Pseudomonas aeruginosa pcrv binding single variable domain antibodies
US9777055B2 (en) * 2012-04-20 2017-10-03 Thomas Jefferson University Engineered antibody for inhibition of fibrosis
NZ725398A (en) * 2012-05-25 2018-05-25 Chr Hansen As Variants of chymosin with improved milk-clotting properties
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
US20140314741A1 (en) * 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
US9416197B2 (en) 2013-11-01 2016-08-16 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
CN104805507B (zh) * 2014-01-29 2019-01-22 杭州康万达医药科技有限公司 噬菌体展示文库及其应用和制备方法
RU2739004C1 (ru) 2014-02-26 2020-12-21 Кхр. Хансен А/С Варианты химозина с улучшенными молокосвертывающими свойствами
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
WO2016207214A1 (en) 2015-06-22 2016-12-29 Chr. Hansen A/S Variants of chymosin with improved properties
MX2018002366A (es) 2015-08-31 2018-04-11 Chr Hansen As Variantes de quimosina con propiedades mejoradas.
IL260185B (en) * 2016-01-08 2022-09-01 Momotaro Gene Inc A combination therapy using reic/dkk-3 gene and a checkpoint inhibitor
CA3024211A1 (en) 2016-05-19 2017-11-23 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
JP7395251B2 (ja) 2016-05-19 2023-12-11 セーホーエル．ハンセン アクティーゼルスカブ 改善された凝乳特性を有するキモシン変異体
EP4282969A3 (en) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
MX2020006297A (es) 2017-12-15 2020-12-07 Aleta Biotherapeutics Inc Variantes de cd19.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2078518T3 (es) * 1990-04-05 1995-12-16 Roberto Crea Mutagenesis por desplazamiento completo.
EP0748338A4 (en) * 1994-03-04 2001-03-28 Merck & Co Inc IN VITRO MATURATION OF ANTIBODIES BY MEANS OF ALANINE 'SCANNING' MUTAGENESIS
AU784983B2 (en) * 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092458A1 (ko) * 2012-12-11 2014-06-19 연세대학교 산학협력단 코돈 조합화 및 변이유발을 이용한 유전자 라이브러리의 합성 방법
US10036007B2 (en) 2012-12-11 2018-07-31 Celemics, Inc. Method of synthesis of gene library using codon randomization and mutagenesis

Also Published As

Publication number Publication date
AU2004254352A1 (en) 2005-01-13
CN1836041A (zh) 2006-09-20
JP5358604B2 (ja) 2013-12-04
EP1660655A2 (en) 2006-05-31
EP1660655B1 (en) 2016-11-02
US20050136428A1 (en) 2005-06-23
WO2005003345A3 (en) 2005-03-24
CA2542192A1 (en) 2005-01-13
ZA200510460B (en) 2006-11-29
ES2609102T3 (es) 2017-04-18
JP4791960B2 (ja) 2011-10-12
IL172736A0 (en) 2006-04-10
JP2007524390A (ja) 2007-08-30
BRPI0412007A (pt) 2006-08-15
WO2005003345A2 (en) 2005-01-13
NO20060108L (no) 2006-03-24
JP2011182794A (ja) 2011-09-22
CA2542192C (en) 2013-05-28
RU2005140664A (ru) 2007-08-27

Similar Documents

Publication Publication Date Title
CA2542192C (en) Look-through mutagenesis
JP4939410B2 (ja) 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発
US7175996B1 (en) Methods of optimizing antibody variable region binding affinity
KR20210144698A (ko) 항체 최적화를 위한 변이 핵산 라이브러리
JPH06510671A (ja) キメラ抗体の製造−組合せアプローチ
US20110136695A1 (en) Universal libraries for immunoglobulin
JP5143551B2 (ja) ユニバーサル抗体のライブラリー
CA2482769A1 (en) "doping" in walk-through mutagenesis
MXPA06000080A (en) Look-through mutagenesis
AU8021900B2 (https=)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051227

Patent event code: PA01051R01D

Comment text: International Patent Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20060310

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid